Renal ImpairmentPhase 1NCT02508506
Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
A Phase 1 study testing ALKS 5461 in people with Renal Impairment, run by Alkermes, Inc. at 3 sites in United States.
Trial summary
This study will evaluate the effect of various degrees of renal function on the pharmacokinetics and safety of ALKS 5461. Read more about this study
- Who is it for?
- Ages 18 to 79 yearsHealthy volunteers can take part
- Conditions the study is for
- Renal Impairment
- What is being tested?
- ALKS 5461
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 22 participants
- Where
- 3 sitesUnited States
- Study dates
- Jul 2015to Dec 2015
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 79 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- For all subjects:
- Has a body mass index (BMI) of 18.0-40.0 kg/m^2 and a total body weight >50kg
- Agrees to use an approved method of contraception for the duration of the study
- Additional criteria may apply
- For subjects with renal impairment:
- Has severe or end stage renal disease, and does not require dialysis
- Has stable renal function for at least 60 days preceding screening
- Additional criteria may apply
Who cannot join
- For all subjects:
- Has any past history or current finding of a clinically significant observed abnormality, psychiatric or medical condition other than renal impairment
- Has a history of gastrointestinal surgery affecting drug absorption or biliary elimination, excluding appendectomy or cholecystectomy
- Is pregnant, planning to become pregnant, or lactating
- Has a history of clinically significant allergy or a hypersensitivity to opioids
- Additional criteria my apply
Show all 10Show fewer
- For subjects with renal impairment:
- Has evidence of compromised respiratory function, seizure disorder, or myasthenia gravis
- Has received a kidney transplant
- Additional criteria may apply
Trial locations and contacts
3 sites in 1 country.
United States3 sites
Alkermes Investigational SIte
Denver, Colorado, 80228
Alkermes Investigational Site
Minneapolis, Minnesota, 55404
Alkermes Investigational SIte
Orlando, Florida, 32809
About this study
Official title: A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS5461 in Subjects With Renal Impairment
This study will evaluate the effect of various degrees of renal function on the pharmacokinetics and safety of ALKS 5461.
- Conditions
- Renal Impairment
- Being tested
- ALKS 5461
- Keywords
- ALKS 5461, Alkermes, Samidorphan, Renal Impairment, Pharmacokinetics, Buprenorphine
- Medical subject headings
- Renal Insufficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ALKS 5461Drug
Single dose, given orally
| Study group | Role | What they receive |
|---|---|---|
| ALKS 5461 | Experimental | Sublingual tablet Receives: Drug: ALKS 5461 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area under the plasma concentration versus time curve from time 0 to infinity (AUC0-inf) following a single dose of ALKS 5461
Measured: up to 168 hours postdose
Area under the plasma concentration versus time curve from time 0 to time of last measurable concentration (AUC0-last) following a single dose of ALKS 5461
Measured: up to 168 hours postdose
Maximum observed plasma concentration (CMAX) following a single dose of ALKS 5461
Measured: up to 168 hours postdose
Secondary outcomes (5)
Time to reach maximum plasma concentration (TMAX)
Measured: up to 168 hours postdose
Terminal elimination half-life (T1/2)
Measured: up to 168 hours postdose
Apparent clearance (CL/F)
Measured: up to 168 hours postdose
Apparent volume of distribution (Vz/F)
Measured: up to 168 hours postdose
Safety: Incidence of adverse events (SAE)
Measured: Up to 12 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jul 2015 (estimated)
- Study startJul 2015
- Primary completionDec 2015
- Study completionDec 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Renal ImpairmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alkermes, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Arielle Stanford, MD, Study director, Alkermes, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02508506
- Sponsor's protocol ID
- ALKS5461-A108
- Status last verified
- Feb 2016
- First submitted
- 23 Jul 2015
- Last updated
- 4 Feb 2016
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Feb 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS5461 in Subjects With Renal Impairment
- ClinicalTrials.gov ID
- NCT02508506
- Acronym / sponsor ID
- ALKS5461-A108
- Conditions
- Renal Impairment
- Keywords
- ALKS 5461, Alkermes, Samidorphan, Renal Impairment, Pharmacokinetics, Buprenorphine
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 22 participants (actual)
- Lead sponsor
- Alkermes, Inc.Industry (pharma, biotech, devices)
- Study start
- Jul 2015
- Primary completion
- Dec 2015 (actual)
- Study completion
- Dec 2015 (actual)
- First posted
- 27 Jul 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the effect of various degrees of renal function on the pharmacokinetics and safety of ALKS 5461.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| ALKS 5461 | Experimental | Drug: ALKS 5461Sublingual tablet |
Who may qualify
- Ages
- 18 to 79 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Has a body mass index (BMI) of 18.0-40.0 kg/m^2 and a total body weight >50kg
- Agrees to use an approved method of contraception for the duration of the study
- Additional criteria may apply
- Has severe or end stage renal disease, and does not require dialysis
- Has stable renal function for at least 60 days preceding screening
Key exclusion criteria (10 listed)
- Has any past history or current finding of a clinically significant observed abnormality, psychiatric or medical condition other than renal impairment
- Has a history of gastrointestinal surgery affecting drug absorption or biliary elimination, excluding appendectomy or cholecystectomy
- Is pregnant, planning to become pregnant, or lactating
- Has a history of clinically significant allergy or a hypersensitivity to opioids
- Additional criteria my apply
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ALKS 5461Single dose, given orally | Drug | ALKS 5461 |
Primary outcome
Area under the plasma concentration versus time curve from time 0 to infinity (AUC0-inf) following a single dose of ALKS 5461
Time frame: up to 168 hours postdose
Area under the plasma concentration versus time curve from time 0 to time of last measurable concentration (AUC0-last) following a single dose of ALKS 5461
Time frame: up to 168 hours postdose
Maximum observed plasma concentration (CMAX) following a single dose of ALKS 5461
Time frame: up to 168 hours postdose
5 secondary outcomes
Time to reach maximum plasma concentration (TMAX)
Time frame: up to 168 hours postdose
Terminal elimination half-life (T1/2)
Time frame: up to 168 hours postdose
Apparent clearance (CL/F)
Time frame: up to 168 hours postdose
Apparent volume of distribution (Vz/F)
Time frame: up to 168 hours postdose
Safety: Incidence of adverse events (SAE)
Time frame: Up to 12 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Feb 2016.
Related trials for Renal Impairment
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Arielle Stanford, MD study director
Alkermes, Inc.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing ALKS 5461 in people with Renal Impairment, run by Alkermes, Inc. at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area under the plasma concentration versus time curve from time 0 to infinity (AUC0-inf) following a single dose of ALKS 5461 (time frame: up to 168 hours postdose). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2016.